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Abstract 
AmpC β-lactamases hydrolyze penicillins, cephalosporins and cephamycins and resist inhibition by clavulanate, 
sulbactam, and tazobactam. Strains with AmpC genes are inherently resistant to multiple agents, making the 
selection of an effective antibiotic difficult. This present work sought to investigate the occurrence of AmpC 
beta-lactamases-producing phenotypes in E. coli and K. pneumoniae and their antimicrobial sensitivity profile. 
Four hundred K. pneumoniae and E. coli non-duplicate isolates were collected and their antibiotic sensitivity 
testing for cefoxitin and other 16 antibiotics were determined using Vitek 2 Compact System (bioMérieux, 
Marcy I’Etoile, France).  The isolates resistant to cefoxitin were confirmed as AmpC beta-lactamases-producing 
phenotypes with disk synergy testing (DST) using cefotaxime or ceftazidime with or without boronic acid. An 
increase in zone diameter of ≥5mm in the presence of boronic acid indicates the presence of AmpC beta-
lactamases in the test organism. The results showed that of the 50 cefoxitin resistant isolates screened from 400 
bacterial isolates, 5(10%) were AmpC beta-lactamase-producers with 60%, 60%, 60%, 80% and 100% multiply 
antibiotic resistance in gentamicin, ciprofloxacin, norfloxacin, trimethoprim/sulfamethoxazole and tetracycline 
respectively. Nitrofurantoin which indicated 100% susceptibility with MIC90 of 32µg/ml may be a therapeutic 
option especially for non-life-threatening urinary tract infection. Imipenem was the antibiotic of choice with 
100% susceptibility rates (MIC90 of ≤1µg/ml). Though the insignificant (p>0.05) levels of AmpC beta-lactamase 
phenotypes may not require routine detection in health facilities, there is the need to implement evolutionary 
antibiotic administration policies and pragmatic infection control measures in the hospitals.       
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1.0 Introduction 
AmpC β-lactamases hydrolyze penicillins, cephalosporins and cephamycins and resist inhibition by clavulanate, 
sulbactam, and tazobactam. Many gram-negative bacilli produce a chromosomally mediated AmpC which, when 
hyperproduced, may cause resistance to penicillins, aztreonam, cephamycins, and cephalosporins (Thomson, 
2010). The genetic determinants for AmpC β-lactamases are commonly found on the chromosomes of genera 
such as Enterobacter and Citrobacter, but have now transferred onto plasmids and spread to other organisms, 
including E. coli and Klebsiella (Heffernan et al., 2007). AmpC beta-lactamase-producing organisms are 
resistant to cefoxitin. Cefoxitin resistance can also be caused by certain carbapenemases and by decreased levels 
of production of outer membrane porins affecting permeability to β-lactams in both K. pneumoniae and E. coli. 
Nevertheless, cefoxitin resistance is said to be a discriminative parameter for the detection of AmpC-producing 
strains (Peter-Getzlaff et al., 2011). AmpC beta-lactamases are known to be inhibited by boronic acid and 
cloxacillin (Jacoby, 2009). Bacteria with AmpC genes are often resistant to multiple antimicrobials of different 
classes, making the selection of an effective antibiotic difficult. This work seeks to investigate the occurrence of 
AmpC beta-lactamases-producing phenotypes in E. coli and K. pneumoniae and their antimicrobial sensitivity 
profile. 
 
2.0 Materials and Methods 
2.1 Materials 
Glycerol broth, blood agar and MacConkey agar were prepared according to manufacturers’ guidelines.  
Cefotaxime, ceftazidime and boronic acid.antibiotics discs were used for AmpC beta-lactamase phenotype 
confirmation.  Vitek 2 Compact System (bioMérieux, Marcy I’Etoile, France) was used to identify the isolates, 
determine minimum inhibition concentration of selected antibiotics and interpret the MICs according to CSLI 
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2.2 Sample Size 
A sample size of 400 K. pneumoniae and E. coli were collected from the Central Laboratory of the Korle Bu 
Teaching Hospital (KBTH) and Advent Clinical Laboratories; both in the Accra Metropolis, Ghana. This 
corresponds with the standard techniques used to calculate the minimum sample size based on the expected 
prevalence and using appropriate levels of precision at 95% confidence level.  
2.3 Inclusion Criteria 
Non-duplicate pure cultures of K. pneumoniae and E. coli which are resistant to cefoxitin. 
2.4 Exclusion Criteria 
All K. pneumoniae and E. coli isolates not resistant to cefoxitin. 
2.5 Identification of Bacterial Isolates, Determination of Minimal Inhibition Concentration (MIC) and Antibiotic 
Sensitivity Testing 
The lactose fermenting isolates were sub-cultured on blood and MacConkey agar and incubated at 35°C for 24 
hours. The pure colonies were gram-stained to confirm their Gram negative reaction. K. pneumoniae and E. coli 
were identified based on their Gram stain reaction and biochemical reaction characteristics in the ID test cards 
wells using Vitek 2 system.  The Vitek 2 system uses the micro-dilution method to determine the MICs of the 
antibiotics. Each AST card contains dried antibiotics with a microbiological culture medium in varying 
concentrations. The 17 antibiotics used were ampicillin, amoxicillin/clavulanic acid, piperacillin, 
piperacillin/tazobactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, amikacin, 
gentamicin, ciprofloxacin, Norfloxacin, tetracycline, nitrofurantoin, trimethoprim/ sulfamethoxazole. The Vitek 
2 system (bioMérieux, Marcy I’Etoile, France) performs antimicrobial sensitivity testing (AST) based on kinetic 
analysis of growth data. The therapeutic significance of the MIC of the antimicrobials was determined using the 
Vitek 2 Compact system. At the end of the incubation cycle, MIC values and their interpretations (susceptible, 
resistant and indeterminate) were generated for each antibiotic.  
2.6 Detection of ESBL Phenotype using AmpC beta-lactamases-producing phenotypes 
AmpC beta-lactamases producers were detected by disk synergy testing (DST) using cefotaxime or ceftazidime 
with or without boronic acid. Using a pure culture of the test organism that were resistant to cefoxitin, a 
suspension in distilled water equivalent in density to a McFarland 0.5 opacity standard was prepared. Using a 
sterile swab, the suspension was spread uniformly across the surface of Mueller-Hinton agar plate. Using a 
sterile forceps, cefotaxime or ceftazidime with or without boronic acid was placed onto the inoculated medium 
ensuring that they were evenly spaced. The plates were incubated aerobically at 35-37°C for 18 – 20 hours. The 
diameter of any zones of inhibition was measured and recorded. The zone of inhibition for the ceftazidime and 
cefotaxime was compared to that of the ceftazidime and cefotaxime plus boronic acid combination disks. An 
increase in zone diameter of ≥5mm in the presence of boronic acid indicates the presence of AmpC beta-
lactamases in the test organism. 
2.7 Statistical Analyses 
The data from the work was collated and statistically analysed using one-way analysis of variance (ANOVA)      
. Results were considered significant if p<0.05. 
 
3.0 Results 
3.1 Bacterial Isolates and AmpC beta-lactamases-Producing Phenotypes 
Among the 400 bacterial isolates, 50 were resistant to cefoxitin of which 29 were K. pneumonia and 21 were E. 
coli as shown in table 1 and table 2. Of the 50 cefoxitin resistant isolates, 5(10%) were AmpC Beta-lactamase-
producers as indicated in table 3. Only 5(1.3%) of all the 400 bacterial isolates produced AmpC Beta-lactamase 
as shown in table 4. 
 
Table 1:                         Number of Bacterial Isolates  
                                                                  Number % 
 
                            K. pneumoniae                   E. coli                        Total 
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Table 2:      Number of Isolates Resistant to Cefoxitin  
                                                                        Number (%)  
                   K. pneumoniae                                    E. coli                             Total            
                        n=175                                            n=225                             n=400              
                        29(16.6)                                        21(9.3)                         50(12.5)         
 
 
Table 3: AmpC Beta-lactamase-producing Phenotypes among   All Cefoxitin Resistant Isolates 
                                                                              Number (%) 
                            K. pneumoniae                                  E. coli                         All Isolates         
                                   n=29                                           n=21                           n=50                                                                                
                                  2(6.9)                                           3(14.3)                       5(10.0)  
       
Table 4:               AmpC Beta-lactamase-producing Phenotypes among   All Isolates 
                                                                Number (%) 
                            K. pneumoniae                                    E. coli                         All Isolates         
                                n=175                                           n=225                               n=400                                                                               
                                  2(1.1)                                           3(1.3)                              5(1.3)  
 
3.2 Antimicrobial Susceptibility among AmpC Beta-lactamase-producing Phenotypes  
Of the 5 AmpC beta-lactamase-producing organisms, none (0.0%) was susceptible to ampicillin, 
amoxicillin/clavulanic acid, piperacillin, cefazolin, cefoxitin and tetracycline as shown in table 5. Of the 5 AmpC 
beta-lactamase-producing phenotypes, 20% of cefotaxime and ceftazidime had MICs that were susceptible and 
40% of the MIC of cefepime was in the susceptible breakpoint as shown in table 5 though all cephalosporins are 
considered to be resistant to AmpC beta-lactamase producers. Forty percent (40%) were susceptible to 
piperacillin/tazobactam combination with their MIC50 and MIC90 being 8µg/ml and 16µg/ml respectively as 
indicated in table 5. Hundred percent (100%) of imipenem and nitrofurantoin and 60% of amikacin were 
susceptible to the AmpC beta-lactamase-producing organisms. Of the 5 AmpC beta-lactamase-producers, 20% 
were susceptible to gentamicin with their MIC50 and MIC90 being ≤1µg/ml and ≤1µg/ml respectively as 
indicated in table 5. Forty percent (40%) of the AmpC beta-lactamase producers were susceptible to 
ciprofloxacin and norfloxacin. Of the 5 AmpC beta-lactamase producers, 20% were susceptible to 
trimethoprim/sulfamethoxazole with their MIC50 and MIC90 being ≤20µg/ml and ≤20µg/ml respectively as 
indicated in table 5.                               
 
Table 5:       Antimicrobial Susceptibility Profile among AmpC- Beta-lactamase  Producing Phenotypes 
Antimicrobial Agent                 No. (%) of Susceptible Isolates           MIC (µg/ml) 
AmpC Producers (n=5)                             Breakpoint Range           MIC50     MIC90 
Ampicillin                                  0(0)            ≤2  16   ≥32               ***  ***             
Amoxicillin/Clavulanic acid      0(0)             ≤2  16   ≥32                     ***  *** 
Piperacillin                                 0(0)                 ≤4  32-64  ≥128              ***  ***       
Piperacillin/Tazobactam            2(40)               ≤4  32   ≥128       ≤4 ≤4 
Cefazolin                                    0(0)                 ≤4  16  ≥ 64                     *** ***              
Cefoxitin                                    0(0)                 ≤4  16   ≥ 64                    *** *** 
Cefotaxime                                1(20)                ≤1  16   ≥ 64            ≤1 ≤1  
Ceftazidime                               1(20)                 ≤1  16   ≥ 64           8 8   
Cefepime                                   2(40)                 ≤1  16   ≥ 64                 ≤1   8    
Imipenem                                  5(100)               ≤1   8   ≥ 16             ≤1 ≤1            
Amikacin                                   3(60)                 ≤2  32  ≥64  ≤2 ≤2               
Gentamicin                                1(20)                 ≤1    8   ≥16                   ≤1 ≤ 1   
Ciprofloxacin                            2(40)                 ≤0.25  2  ≥ 4                  ≤0.25      1     
Norfloxacin                               2(40)      ≤0.5  8  ≥16                    2 2  
Tetracycline                               0(0)        ≤1    8  ≥16                     ***       ***   
Nitrofurantoin                           5(100)              ≤16  64 ≥512                   ≤16 32   
Trimethoprim/Sulfamethoxazole 1(20)             ≤20 80 ≥320                    ≤20 ≤20                                                                    
MIC50: MIC at which 50% of the AmpC- Beta-lactamase Producing Phenotypes were susceptible to a particular 
antimicrobial agent        
MIC90: MIC at which 90% of the AmpC- Beta-lactamase Producing Phenotypes were susceptible to a particular 
antimicrobial agent                                 
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3.3 Antimicrobial Resistance among AmpC Beta-lactamase-producing Phenotypes 
Of the 5 AmpC beta-lactamase producing organisms, all (100%) were resistant to ampicillin, piperacillin, 
cefazolin, and tetracycline as shown in table 6. Forty percent (40%) and 20% of piperacillin/tazobactam and 
amoxacillin/clavulanic acid respectively were resistant to AmpC beta-lactamase-producing phenotypes. Sixty 
percent (60%) of cefotaxime and cefepime had MICs that were resistant to the 5 AmpC beta-lactamase-
producing phenotypes and 40% of the MIC of ceftazidime were in the resistant breakpoint as shown in table 6. 
None (0%) of imipenem and nitrofurantoin and 20% of amikacin was resistant to the AmpC beta-lactamase-
producing organisms. Of the 5 AmpC beta-lactamase-producers, 60% were resistant to gentamicin, ciprofloxacin 
and norfloxacin. Of the 5 AmpC beta-lactamase producers, 80% were resistant to 
trimethoprim/sulfamethoxazole with their MIC50 and MIC90 being ≥320µg/ml and ≥320µg/ml respectively as 
indicated in table 6. 
Table 6. Antimicrobial Resistance Profile among AmpC- Beta-lactamase Producing Phenotypes 
Antimicrobial Agent                    No. (%) of Resistant Isolates               MIC (µg/ml) 
AmpC Producers (n=5)                            Breakpoint Range                 MIC50     MIC90 
Ampicillin                                  5(100)            ≤2  16 ≥32   ≥ 32 ≥ 32      
Amoxicillin/Clavulanic acid      2(40)             ≤2  16  ≥ 32             8 ≥ 32 
Piperacillin                                 5(100)             ≤4  32-64  ≥128        ≥128     ≥128            
Piperacillin/Tazobactam            1(20)               ≤4  32 ≥128        ≥128     ≥128     
Cefazolin                                   5(100)             ≤4  16  ≥ 64           ≥ 64     ≥ 64            
Cefoxitin                                    5(100)             ≤4  16 ≥ 64            32 ≥ 64     
Cefotaxime                                3(60)                ≤1 16  ≥ 64                     ≥ 64 ≥ 64 
Ceftazidime                               2(40)               ≤1  16  ≥ 64             32 32 
Cefepime                                   3(60)               ≤1  16  ≥ 64             32 32 
Imipenem                                  0(0)                 ≤1   8   ≥ 16                      ***        ***         
Amikacin                                   1(20)               ≤2  32  ≥ 64  ≥ 64 ≥ 64               
Gentamicin                                3(60)               ≤1    8  ≥16                     ≥ 16 ≥ 16          
Ciprofloxacin                            3(60)               ≤0.25 2  ≥ 4                      ≥ 4 ≥ 4  
Norfloxacin                               3(60)    ≤0.5 8  ≥16                       ≥16 ≥16   
Tetracycline                              5(100)      ≤1    8   ≥16               ≥16 ≥16    
Nitrofurantoin                           0(0)                 ≤16  64 ≥512                   ***        ***    
Trimethoprim/Sulfamethoxazole 4(80)            ≤20 80 ≥320                    ≥320 ≥320                                                                     
MIC50: MIC at which 50% of the AmpC- Beta-lactamase Producing Phenotypes were resistant to a particular 
antimicrobial agent        
MIC90: MIC at which 90% of the AmpC- Beta-lactamase Producing Phenotypes were resistant to a particular 
antimicrobial agent                              
 
4.0 Discussion 
Fifty bacterial isolates were resistant to cefoxitin therefore potential producers of plasmid-mediated AmpC beta-
lactamses (PMACBL). The occurrence of plasmid-mediated AmpC-producing strains is typically less common 
in most parts of the world (Jacoby, 2009). This low occurrence was reflected in this present work which recorded 
an insignificant (p>0.05) 5(10%) of the 50 cefoxitin resistant isolates as plasmid-mediated AmpC beta-lactamase 
producers. Of these 5, 3 were from E. coli and the remaining 2 were from K. pneumoniae. The low occurrence of 
AmpC beta-lactamase producers was consistent with the work of Heffernan and colleagues (2007) in New 
Zealand who reported that 6(18.2%) of 33 cefoxitin resistant E. coli isolates were AmpC beta-lactamase 
producers. However, in that work none of the K. pneumoniae isolates carried AmpC genes which deviated from 
this present work, though E. coli is deemed to be a successful producer of plasmid-mediated AmpC beta-
lactamase (PMACBL). There is no published work on the occurrence of PMACBL in Accra, Ghana.   
Strains with AmpC genes are inherently resistant to multiple agents, making the selection of an effective 
antibiotic difficult. Most cephalosporins, penicillins and β-Lactam/β-lactamase inhibitor combinations should be 
avoided because of in vivo resistance, the potential for AmpC induction or selection of high-enzyme-level 
mutants and documented poor clinical outcomes with ceftazidime, cefotaxime, and piperacillin-tazobactam 
(Jacoby, 2009). Cefepime is a poor inducer of AmpC β-lactamase which rapidly penetrates through the outer cell 
membrane. However, Jacoby (2009) reported that cefepime MICs increase dramatically for some AmpC 
producers, suggesting caution in its use, and some strains are frankly resistant. This was consistent with the 
present work which indicated 60% resistance of cefepime to AmpC beta-lactamase producers with MIC90 of 
32µg/ml as shown in table 6 though 40% were susceptible with raised MIC90 of 8µg/ml as demonstrated in table 
5. Amikacin had a good activity against AmpC beta-lactamase producers with MIC90 of ≤2µg/ml. Nitrofurantoin 
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and imipenem indicated 100% susceptibility to AmpC beta-lactamase producers with MIC90 of 32µg/ml and 
≤1µg/ml respectively as shown in table 5. Carbapenem therapy has usually been successful when it does not lead 
to the emergence of carbapenem-resistant isolate associated with ACT-1 β-lactamase production and outer 
membrane porin loss (Jacoby, 2009). If the isolate is susceptible, nitrofurantoin therapy may be an option 
especially for non-life-threatening infections such as urinary tract infection. 
 
5.0 Conclusion 
The findings of this work indicated 5(10%) of AmpC beta-lactamase phenotypes among 50 cefoxitin resistant 
isolates screened from 400 Escherichia coli and Klebsiella pneumoniae in Accra. The AmpC beta-lactamase 
phenotypes exhibited multiple drug resistance of 60%, 60%, 60%, 80% and 100% to gentamicin, ciprofloxacin, 
norfloxacin, trimethoprim/sulfamethoxazole and tetracycline respectively. Nitorfurantoin which showed 100% 
susceptibility to AmpC beta-lactamase producers may be used in treating non-life threating urinary tract 
infections. Imipenem which is considered to be the antibiotic of choice indicated 100% susceptibility with 
MIC90 being ≤1µg/ml.    
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